Skip to main content
. 2022 Aug 10;49(11):1106–1117. doi: 10.1111/1346-8138.16543

FIGURE 3.

FIGURE 3

Cost associated with persistence and switching. (a) Cost for patients persisting on index treatment for 12 months and (b) cost for patients who switched to other treatments in the 12‐month follow‐up period. IL, interleukin; JPY, Japanese Yen; n, number of patients; PDE‐4, phosphodiesterase‐4; PPPM, per person per month. Includes biologics received by < 20 patients. Error bars indicate 95% confidence intervals.